Tumor metastases to distant organs cause the majority of mortality in breast cancer. There is currently no effective treatment for metastatic breast cancer. We hypothesize that metastatic breast cancer can be effectively treated through targeting the DNA damage response pathways with tissue-specific enrichment of therapeutics. Thus, targeted therapy is achieved through tumor tissue-targeted delivery of targeted therapeutics. We have recently developed a polycation-functionalized nanoporous silicon (PCPS) technology platform for siRNA delivery. This platform has a high loading capacity and protects siRNA from degradation by plasma and tissues enzymes. In addition, it maintains sustained release of therapeutic siRNA nanoparticles that are formed in situ during nanoporous silicon degradation for effective tumor cell uptake. We have also shown that the tumor vascular endothelial cells express a high level of E-selectin, and that an E-selectin thioaptamer (ESTA) binds to the tumor vasculature with high affinity and specificity. In this application, we will functionalize the surface of the PCPS particles with the tumor vasculature-targeting moiety to achieve tumor-specific delivery of siRNA. The system will be applied to treat metastatic breast cancer with focus on triple negative breast cancer (TNBC). TNBC is a sub-group of breast cancer with the lowest treatment success rate. Chemo/radiation therapy induces genome damage that evokes DNA damage response whose primary regulator is the ATM kinase. Down-regulation of ATM kinase enhances cancer cell sensitivity. We will develop an effective treatment through blocking DNA damage response by focusing these Specific Aims:
Aim 1. To develop a tumor vasculature-targeted high capacity carrier for siRNA and to study transport of therapeutic siRNA to tumor cells Aim 2. To test synergy between suppression of ATM expression and chemotherapy on killing of human TNBC cells Aim 3. To evaluate therapeutic efficacy from tumor vasculature-targeted ATM siRNA in murine xenograft model of human TNBC bone metastasis and PDX model of breast cancer lung metastasis These studies will demonstrate the effectiveness of tumor tissue-enriched ATM siRNA on sensitizing chemotherapy, and will pave the way for the development of the novel siRNA therapeutics for metastatic breast cancer.

Public Health Relevance

In late-stage breast cancer patients, the tumor cells have metastasized to multiple organs such as the lung and bone. In order to treat cancer patients effectively, it is essential to enrich drugs in these metastatic organs so that the tumor cells can be effectively targeted. Our new technology platform will deliver cancer therapeutics specifically to the tumor tissues taking advantage of the unique protein expression profile of tumor blood vessels, and enable effective cell killing by blocking cancer cell's ability to repair their damage DNA. Success in the proposed study will help increase survival of about 40,500 women and men who die each year from breast cancer; nearly 90% of these deaths are due to cancer metastasis to distant organs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Kondapaka, Sudhir B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Methodist Hospital Research Institute
Other Domestic Non-Profits
United States
Zip Code
Shen, Jianliang; Zhang, Wei; Qi, Ruogu et al. (2018) Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics. Chem Soc Rev 47:1969-1995
Mu, Chaofeng; Wu, Xiaoyan; Zhou, Xinyu et al. (2018) Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer. Clin Cancer Res 24:4900-4912
Mai, Junhua; Li, Xin; Zhang, Guodong et al. (2018) DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement. Mol Pharm 15:1814-1825
Liu, Haoran; Mai, Junhua; Shen, Jianliang et al. (2018) A Novel DNA Aptamer for Dual Targeting of Polymorphonuclear Myeloid-derived Suppressor Cells and Tumor Cells. Theranostics 8:31-44
Wang, Feng; Xia, Xiaojun; Yang, Chunying et al. (2018) SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy through Promotion of Autophagy. Clin Cancer Res 24:3176-3185
Shen, Haifa; Sun, Tong; Hoang, Hanh H et al. (2017) Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol 34:114-122
Shen, Jianliang; Kim, Han-Cheon; Wolfram, Joy et al. (2017) A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer. Nano Lett 17:2913-2920
Persano, Stefano; Guevara, Maria L; Li, Zhaoqi et al. (2017) Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials 125:81-89
Shen, Jianliang; Wolfram, Joy; Ferrari, Mauro et al. (2017) Taking the vehicle out of drug delivery. Mater Today (Kidlington) 20:95-97
Ban, Yi; Mai, Junhua; Li, Xin et al. (2017) Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity. Cancer Res 77:2857-2868

Showing the most recent 10 out of 13 publications